Business
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it will host a post-ERA data presentation on Tuesday, June 20, 2023 at 8:00 AM ET. The event will feature Richard Lafayette, M.D., F.A.C.P. (Stanford University Medical Center), discussing week 36 data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN), which are initially being presented as a late-breaking clinical trial at the 60th European Renal Association (ERA) Congress on June 17, 2023. Atacicept is a potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). A live question and answer session will follow the formal presentation. To register for the webinar, please click here. About Richard Lafayette, M.D., F.A.C.P.Dr. Lafayette is a Professor of Medicine (Nephrology) and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center. Dr. Lafayette completed his medical education at New York Medical College and went on to complete his residency at the Long Island Jewish Medical Center, and his fellowship at Stanford University School of Medicine. Dr. Lafayette is board-certified in Internal Medicine and Nephrology. Dr. Lafayette served as the Associate Chair of the Stanford University Department of Medicine from 2002 – 2007, the Clinical Chief of Nephrology at Stanford University from 1999 – 2012, and currently serves as the Director of the Stanford Glomerular Disease Center since 2010. Dr. Lafayette was honored in America’s Top Doctors, Best Doctors from 2004 – 2018, and received America’s Top Doctors Award, Castle Connolly Medical Ltd. from 2014 – 2022. Dr. Lafayette has been part of the following boards and professional organizations: Editorial Board, Kidney News, American Society of Nephrology (2010 - 2021) Member, Glomerular Disease Advisory Committee, American Society of Nephrology (2013 - 2017) Member (ex-officio), Communications Committee, American Society of Nephrology (2015 – Present). About the Phase 2b ORIGIN clinical trial The Phase 2b ORIGIN clinical trial (NCT04716231) is a global, multicent...